Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified October 2013 by University of Bari
Information provided by (Responsible Party):
Flavia Indrio, University of Bari Identifier:
First received: September 18, 2013
Last updated: October 7, 2013
Last verified: October 2013

The primary objective of this trial is to show that an hypoallergenic infant starter formula containing starch and the probiotic L. reuteri decreases the severity of regurgitation/spitting-up in infants presenting regurgitation/spitting-up , and who have taken it for 4 weeks, in comparison with a standard infant starter formula.

Condition Intervention Phase
Regurgitation, Gastric
Dietary Supplement: HA formula + starch + L. reuteri
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying

Resource links provided by NLM:

Further study details as provided by University of Bari:

Primary Outcome Measures:
  • Regurgitation [ Time Frame: four weeks of treatment ] [ Designated as safety issue: No ]
    The primary outcome is the difference in the proportions of improved subjects at four weeks of treatment between the treatment and control groups.

Secondary Outcome Measures:
  • Growth [ Time Frame: Four weeks of treatment ] [ Designated as safety issue: No ]
    To assess whether the groups have comparable growth

  • Regurgitation score [ Time Frame: Four weeks treatment ] [ Designated as safety issue: No ]
    To assess the severity of regurgitation/spitting-up To assess the frequency of regurgitation/spitting-up To assess the volume of regurgitation/spitting-up

  • Gastric empty rate [ Time Frame: Four week treatment ] [ Designated as safety issue: No ]
    To compare the ultrasound gastric empty rate

  • Digestive tolerance [ Time Frame: Four weeks treatment ] [ Designated as safety issue: No ]
    To assess the infants' digestive tolerance

  • Stool frequency [ Time Frame: Four weeks treatment ] [ Designated as safety issue: No ]
    To assess stool frequency

  • compliance [ Time Frame: four weeks intervention ] [ Designated as safety issue: No ]
    To assess the subject's compliance to product consumption.

  • Financial and non-financial burden [ Time Frame: Four week treatment ] [ Designated as safety issue: No ]
    To measure family financial and non-financial burden related with the regurgitation

Estimated Enrollment: 132
Study Start Date: October 2013
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Infant formula
HA formula + starch + L. reuteri
Dietary Supplement: HA formula + starch + L. reuteri
Placebo Comparator: Standard Formula
Standard Infant Formula

Detailed Description:

The primary objective of this trial is to show that the test formula (HA formula + starch + L. reuteri) decreases the severity (frequency + volume) of regurgitation/spitting-up in infants and ultrasound gastric emptying time, compared to a classical infant starter formula.


Ages Eligible for Study:   up to 5 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Full term infant (37 weeks ≤ gestation ≤ 42 weeks)
  • Age of infant between 5 days and 5 months
  • NGA
  • Infant exclusively formula-fed at enrollment
  • Presenting regurgitation/spitting-up according to the parents' perception
  • Vandenplas score of at least 2 and maximum 5
  • Having obtained the subject's legal representative's written informed consent

Exclusion Criteria:

  • Previous antireflux treatment
  • Previous consumption of AR infant formula or external thickener
  • Previous consumption of a formula with L. reuteri
  • Cow's milk allergy symptoms according to medical decision
  • Congenital illness or malformation that may affect growth
  • Significant pre-natal and/or post-natal disease
  • Newborn whose parents / caregivers cannot be expected to comply with study procedures
  • Newborn currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01956682

Contact: Flavia Indrio, MD

Ospedale Pediatrico Giovanni XXIII Not yet recruiting
Bari, BA, Italy, 70100
Sponsors and Collaborators
University of Bari
Principal Investigator: Flavia Indrio, MD University of Bari
  More Information

No publications provided

Responsible Party: Flavia Indrio, M.D., University of Bari Identifier: NCT01956682     History of Changes
Other Study ID Numbers: University of Bari
Study First Received: September 18, 2013
Last Updated: October 7, 2013
Health Authority: Italy: Ethics Committee processed this record on February 27, 2015